AAV-based in vivo cell-reprogramming gene therapy; delivers

Class

AAV-based in vivo cell-reprogramming gene therapy; delivers reprogramming genes to convert resident astrocytes in the putamen directly into dopaminergic neurons

Pathway

In situ astrocyte-to-dopaminergic-neuron conversion to restore local dopamine production in the putamen

Notes

original target text: AAV-based in vivo cell-reprogramming gene therapy; delivers reprogramming genes to convert resident astrocytes in the putamen directly into dopaminergic neurons

This is a gene-therapy approach designed for Parkinson's disease, a condition in which nerve cells that make dopamine degenerate, most consequentially the projections reaching a brain region called the putamen, which coordinates movement. Rather than delivering dopamine-boosting drugs or transplanting new cells, this strategy uses an adeno-associated virus (AAV), a small, non-replicating virus engineered to carry genetic cargo into cells without causing disease, to deliver genes for reprogramming factors directly into the putamen. These factors instruct resident astrocytes, a supportive glial cell type normally involved in maintaining brain tissue rather than signaling, to change identity and become dopamine-producing neurons in place. The rationale is to restore local dopamine synthesis at the exact site where it is depleted, using the patient's own cells rather than transplanted tissue, which could avoid some immune-rejection concerns associated with cell-replacement therapies. This class of approach sits within the broader field of in vivo cellular reprogramming, which seeks to repair tissue by changing the fate of cells already present rather than replacing them. It is relevant wherever a defined, localized population of neurons is lost and a nearby, abundant cell type could be redirected to take over their function.